CIBR members attended the National Institutes of Health and the Food and Drug Administration Joint Leadership Council Stakeholders Meeting on June 2. CIBR also submitted comments recommending that the Council elevate the urgency of developing a regulatory pathway to accelerate the rapid and efficient clinical translation of diagnostic and therapeutic biomarkers. To view the comments submitted please click here.

By |2010-06-17T20:09:05-04:00June 17th, 2010|advocacy news, government relations news|Comments Off on CIBR Submits Comments on Biomarkers to NIH-FDA Joint Leadership Council
Go to Top